Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (CSE:
$DOSE.C) (TSXV: $RIV.V) (CSE: $FONE.C) (CSE: $ROMJ.C)
Delta, Kelowna, BC –July 16,
2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its potcast
site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/07161ACB-DOSE-RIV-FONE-ROMJ.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com “potcasts”,
looking at cannabis news, stocks to watch as well as insights from thought
leaders and experts.
In today’s podcast we look at a few early
announcements.
But first, CannabCo Pharmaceutical Corp. Colombia S.A.S., a Colombia based
cannabis cultivator and manufacturer of medical cannabis products, announced that it has completed a definitive
agreement with Invest In Orinoquia for the development of thousands of hectares
of Cannabis and hemp production in the Los Llanos region of Colombia. The joint venture will proceed with the
deployment of "purpose-built" cannabis greenhouses for the
cultivation of cannabis under the medical production laws of Colombia in the
Los Llanos region of the country near Villavicencio. The project has been funded for an initial 5
hectare (538,000 sq/ft) build-out with potential expansion to 240 Hectares of
Cannabis cultivation over the next 5 years.
“We are thrilled to be working with
CannabCo on a project of this magnitude." said Didier Valek, the Executive
Director of Invest in Orinoquia.
"It was important for us to find the right company for the
development of cannabis within the region and we were impressed with CannabCo's
vast knowledge base, professionalism, and existing footprint in Colombia,
making them the perfect choice for a project of this size."
After the initial build-out, CannabCo is
looking to expand rapidly on the footprint with a virtually unlimited amount of
land available to the company and the project.
The Los Llanos region features the perfect environment for growing
Cannabis, with an ample amount of sunlight, water availability, and a stable
annual temperature perfect for cultivation.
CannabCo estimates at least 4 crop rotations per annum yielding an
abundance of high quality product slated for extraction to Cannabis oil. The project will be ICA certified (Colombia's
"Agriculture Institute") and follows GACP and GPP practices for the
cultivation of a food-grade / medical crop.
Already projected to be one of the largest
cannabis producers globally, this latest initiative secures CannabCo as a
primary source for medical Cannabis extracts and products for both domestic
supply and export markets. In addition
to the Los Llanos project, the company recently completed an agreement for the
conversion of approximately 1 Million Sq/ft of greenhouse production in the
Cundinamarca region for cannabis cultivation.
"As an addition to our current
operations, this latest agreement fits perfectly with the company's goals to be
the world leader in cannabis production.
We have established the perfect relationship with Invest in Orinoquia to
assist Colombia in becoming the primary source for medical cannabis
globally," said Joseph Palumbo, CannabCo's General Manager for Colombia,
"Our goal is to increase our cultivation footprint, product manufacturing,
and supply infrastructure to become the largest quality supplier of medical
cannabis in the world," said Joseph.
Cannabco will be providing genetics for
cultivation specific to the Los Llanos region to maximize productivity, yields,
and resistance to local pathogens.
Through the use of targeted genetics, and purpose-built cannabis
greenhouses, management intends for Cannabco's operations to be the most
advanced and productive cultivation operation in South America.
The project is fully funded and is slated
to begin in 2019. Once completed, the
project will begin grow operations and aggressive expansion efforts with the
construction of additional purpose built greenhouses under the CannabCo
License.
"While our primary focus is on medical
Cannabis, we will be pursuing parallel initiatives such as hemp production and
hemp derived CBD to meet market demand and requests for product from our supply
channel." said Joseph.
Rapid Dose Therapeutics Corp. (CSE: DOSE) and
Ukraine Pharma announced today that they have signed a twelve month
distribution agreement to export QuickStrip™ nutraceutical products to Ukraine
and a number of other Eastern European countries, giving the Company rights to
market the Energy, B12, and Sleep QuickStrip™ nutraceutical products to a
consumer base of over 200 million people with tremendous buying power.
The
Agreement requires a minimum quarterly order of one million of each of RDT's
Energy, B12, and Sleep QuickStrips™ and the Company has provided RDT with a
signed purchase order for US$2.1 million.
RDT's
proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™
oral fast-dissolving drug delivery system that offers an Anytime, Anywhere™
product to consumers. Ukraine Pharma expects to distribute QuickStrip™ by the
third calendar quarter of 2019.
"This
represents the beginning of a growing opportunity for RDT to provide its
QuickStrip™ products to people wanting an effective and innovative means of
delivering nutraceuticals," said Mark Upsdell, CEO of RDT. "The
Agreement with Ukraine Pharma elevates QuickStrip™ as a growing international
brand and delivery device to major market consumers, while simultaneously
offering health benefits and improving patient outcomes."
"When
we were introduced to the QuickStrip™ technology and nutraceutical product line,
we knew this will significantly change the way drugs are delivered," said
Veronica Burke, CEO of Ukraine Pharma.
"The high quality product combined with the innovative delivery
system is something we consider is much needed in the numerous Eastern European
countries in which we have established relationships. We will begin distribution in Ukraine and
expand from there."
Canopy
Rivers Inc. (TSXV: RIV) (OTC: CNPOF) today released its financial results for the three and
twelve months ended March 31, 2019. The Company's audited consolidated
financial statements for the twelve months ended March 31, 2019, and its full
Management's Discussion and Analysis for the three and twelve months ended
March 31, 2019, are available under the Company's profile on the System for
Electronic Document Analysis and Retrieval at www.sedar.com and on the Company's website at
www.canopyrivers.com/financials.
"It was a year full of milestones and
significant achievements for Canopy Rivers," said Narbe Alexandrian,
President and Chief Executive Officer of Canopy Rivers. "Anchored by our
go public transaction and listing on the TSX Venture Exchange, eight new
investments, and landmark transactions for certain portfolio companies, we have
strategically positioned ourselves as an accelerator of growth for companies
that we believe are situated to be leaders in the cannabis industry. We are
excited for the future as we continue to discover, evaluate, and invest in ways
that expand our footprint into new channels and markets globally, ultimately
creating value for our shareholders," continued Alexandrian. "With
positive global sentiment towards cannabis on the rise, and Canada's
legalization of edibles, extracts, and topicals coming into force in the fall,
we are optimistic about the growth potential of the cannabis industry in the
coming years."
"With more than $195 million in gross proceeds raised from equity financings and more
than $115 million of
capital deployed into new and existing investments over fiscal 2019, we
continue to position ourselves as leading allocators of capital in this new and
emerging global industry," said Eddie Lucarelli, Chief Financial Officer of
Canopy Rivers. "This past fiscal year represented a period of significant
capacity build-out and operational investment at our portfolio companies. We
are excited to see our partners complete their build-out activities over the
next few quarters, allowing their underlying businesses to scale and accelerate
their individual paths towards the generation of meaningful EBITDA across the
Company's ecosystem."
Flower
One Holdings Inc. (CSE:
FONE) (OTCQB:
FLOOF)
today announced a long-term licensing agreement with
Denver-based Clear Cannabis, Inc. –
who licenses The Clear™, one of eight marquee brands licensed under its parent
company. The Clear product suite was founded by scientists and engineers with
substantial expertise in chemistry, biology, and engineering, and the vision of
carving out a unique space within the cannabis industry. The Clear is the first
manufacturer to bring pure, refined cannabis oil to market globally. Flower One
is now licensed to produce, manufacture, and distribute The Clear's product to
Nevada's cannabis retailers, providing the state's consumers with a consistent
supply of The Clear's popular line of flavorful cannabis oils.
"We
are excited to welcome The Clear to Flower One's growing portfolio of Brand
Partners," said Ken Villazor, President and CEO of Flower One. "This
is our tenth brand partnership to date, aligning with our commitment to expand
the range of cannabis products available to cannabis retailers and consumers in
Nevada, and to contribute to the growing product diversity of the State's retail
market."
Founded
in 2013, The Clear has established itself as the first and original cannabis
distillation company. Featuring a robust menu of 17 flavorful vape cartridges,
among other high-quality products, The Clear utilizes steam-distilled plant
extracts and unmatched state-of-the-art technology to provide consumers with a
reliable, clean, and consistent cannabis experience. Soon The Clear's C-Cell
cartridges and top pull batteries will be available in Nevada, providing
cannabis consumers with a consistent dosing experience. Additional vape
cartridges will follow later this year.
Rubicon Organics Inc. (CSE:ROMJ) (OTCQX:ROMJF) announced that
it has received organic certification from the Fraser Valley Organics Producers
Association at its flagship 125,000-square-foot hybrid greenhouse facility in
Delta, BC. As a result, the Company is
now positioned to supply certified organic, super-premium cannabis grown at
scale to a market where organic products are in high demand, short supply and
priced at significant premiums.
"Organic cannabis is highly coveted
in the medical and over-the-counter markets in North America and Europe,"
said Jesse McConnell, Chief Executive Officer and Co-Founder of Rubicon
Organics. "Due to a substantial
lack of supply of high-quality cannabis in the marketplace, there is currently
a 40% to 50% price premium for super-premium cannabis products and an
additional 25% to 50% price premium for organic products in Canada. This is the market that Rubicon Organics is
now well-positioned to serve."
"Having organic certification from
FVOPA is unequivocal validation of our proven, proprietary organic cultivation
methodology which we expect will produce super-premium, certified organic
cannabis at scale and at a competitive cost.
For investors, this means the company expects to achieve
industry-leading gross margins and profitability. For the consumer, Rubicon Organics will
deliver a connoisseur-level experience with the cleanest and most terpene-rich
products on the market."
Rubicon Organics is currently one of just
two cannabis companies in Canada to be certified by FVOPA, Canada's preeminent
certification body for organic operators.
FVOPA's rigorous certification program is compliant with International
Organization for Standardization (ISO) 17065, Canadian Organic Standards and BC
Certified Organic programs.
Rubicon Organics' cannabis is grown in a
proprietary 100% organic soil and fertilizer mix made in-house and developed
over years of organic cannabis cultivation, research and development by the
Company's CSO, who also wrote the Certified Organic Cannabis Standard in Canada
for FVOPA. Rare and semi-rare cannabis
strains are grown without herbicides or pesticides in a sophisticated hybrid
greenhouse environment with exposure to natural sunlight and a fully automated
climate control system ensuring optimal growing conditions year-round.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use
of cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
